CTIS2023-506897-11-00进行中（未招募）1 期
(21177) A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease - 21177
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 1,584
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •A clinical diagnosis of chronic kidney disease and: • Urine albumin/creatinine ratio (UACR) of = 200 but = 3500 mg/g and estimated glomerular filtration rate (eGFR) =25 but <90 mL/min/1.73m^2 at screening, and • Documentation of albuminuria/proteinuria in the participant's medical records at least 3 months prior to screening., Stable and maximum tolerated labeled dose of an Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blocker(ARB) for at least 4 weeks prior to screening, K+ = 4.8 mmol/L at screening
排除标准
- •Established diagnosis of Type 1 or 2 Diabetes mellitus, or HbA1c = 6.5% (48 mmol/mol), Autosomal dominant or autosomal recessive polycystic kidney disease, Lupus nephritis or anti-neutrophilic cytoplasmic autoantibody (ANCA) - associated vasculitis or any other primary or secondary kidney disease requiring immunosuppressive therapy within 6 months prior to screening, Symptomatic heart failure with reduced ejection fraction with class 1A indication for Mineralocorticoid receptor antagonist (MRA)s
研究者
相似试验
进行中（未招募）
1 期
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by anti-cancertherapy in women with, or at high risk for developing hormone-receptor positive breast cancerVasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancerMedDRA version: 20.0Level: LLTClassification code: 10022457Term: Instability vasomotor Class: 10029205MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065CTIS2023-508265-33-00Bayer Consumer Care AG474
招募中
1 期
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosisThrombolysis of symptomatic proximal vein thrombosisMedDRA version: 20.0Level: PTClassification code: 10043568Term: Thrombolysis Class: 100000004865MedDRA version: 21.1Level: LLTClassification code: 10049918Term: Deep venous thrombosis proximal Class: 10047065CTIS2023-503315-15-00Bayer AG255
暂停
2 期
[M20-371]Moderate to Severe Crohn's Disease: A Phase 2 Safety and Efficacy Study of ABBV-154Crohn's diseaseJPRN-jRCT2051210135Yamazaki Hayato265
暂停
2 期
[M20-466] Moderate to Severe Rheumatoid Arthritis: A Phase 2b, Dose-Ranging, Safety and Efficacy Study of ABBV-154Rheumatiod ArthritisJPRN-jRCT2041210052Yamazaki Hayato425
招募中
2 期
[M19-148] A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic StrokeAcute Ischemic StrokeJPRN-jRCT2061210064Otani Tetsuya120